Markers of bone metabolism are affected by renal function and growth hormone therapy in children with chronic kidney disease.

ABSTRACT:

Objectives

The extent and relevance of altered bone metabolism for statural growth in children with chronic kidney disease is controversial. We analyzed the impact of renal dysfunction and recombinant growth hormone therapy on a panel of serum markers of bone metabolism in a large pediatric chronic kidney disease cohort.

Methods

Bone alkaline phosphatase (BAP), tartrate-resistant acid phosphatase 5b (TRAP5b), sclerostin and C-terminal FGF-23 (cFGF23) normalized for age and sex were analyzed in 556 children aged 6-18 years with an estimated glomerular filtration rate (eGFR) of 10-60 ml/min/1.73 m2. 41 children receiving recombinant growth hormone therapy were compared to an untreated matched control group.

Results

Standardized levels of BAP, TRAP5b and cFGF-23 were inc

SUBMITTER: Doyon A 

PROVIDER: S-EPMC4319910 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature